The cholesterol population model: US population requirements for treatment of hypercholesterolemia

American Journal of Managed Care

Volumn 2, Issue 10, 1996, Pages 1362-1370

  Epstein, Robert S ^a   Garrahan, Susan ^a   Nelsen, Linda ^a   Laber, Pamela ^a   Slater, Eve ^a   Berger, Marc L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000133217     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Bethesda, MD: National Heart, Lung, and Blood Institute, National Institutes of Health; September 1993. DHHS publication NIH 93-3095.
2. National Heart, Lung, and Blood Institute. Morbidity and Mortality Chartbook on Cardiovascular, Lung, and Blood Diseases - 1990. Bethesda, MD: National Institutes of Health; 1992:69.
3. Sempos CT, Cooper R, Kovar MG, et al. Divergence of the recent trends in coronary mortality for the four major race-sex groups in the United States. Am J Public Health 1988; 78:1422-1427.
4. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among U.S. adults, The National Health and Nutrition Examination Surveys. JAMA 1993; 269:3002-3008.
5. Hunninghake DB, Stein EA, Dujovne CA, et al. The efficacy of dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia. N Engl J Med 1993; 328:1269-1271.
6. Caggiula AW, Watson JE, Kuller LH, et al. Cholesterol-lowering intervention program: Effect of the step I diet in community office. Arch Intern Med 1996;156:1205-1213.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45). Lancet 1994;344:1383-1389.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 3333:1301-1307.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
10. Nieto FJ, Alonso J, Chambless LE, et al. Population awareness and control of hypertension and hypercholesterolemia. Arch Intern Med 1995;155:677-684.
11. Giles WH, Anda RF, Jones DH, et al. Recent trends in the identification and treatment of high blood cholesterol by physicians. JAMA 1993;269:1133-1138.
12. Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
13. Oster G, Borok GM, Menzin J, et al. Cholesterol-reduction intervention study: A randomized trial to assess effectiveness and costs in clinical practice. Arch Intern Med 1996;156:731-739.
14. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94. Vital Health Stat 1994; 1:20-22. DHHS publication PHS 94-1308.
15. Shear CL, Franklin FA, Stinnett S, et al. Expanded clinical evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins. Circulation 1992; 85:1293-1303.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.
17. Boccuzzi SJ, Robbins D, Weintraub WS. Lovastatin Restenosis Trial Study Group. Effectiveness of high dose lovastatin in coronoary disease: Ability of lovastatin to lower LDL-C below 100 mg/dl. J Invest Med 1996; 44:3, 289a. Abstract.
18. Pederson T, Kjekshus J, Boccuzzi SJ, Epstein RE. Clinical and resource utilization benefits of the Scandinavian Simvastatin Survival Study (4S) applied to the US population. Circulation 1996; 92: 2485. Abstract.
19. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-385.
20. McMillan K. Considerations in the formulary selection of hydroxymethylglutaryl-CoA reductase inhibitors. Am J Health Syst Pharm 1996;53:2206-2214.